Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

The Role of TRP Channels in DPN

NCT07237022 · tracked via the Priya Life Science Belgium tracker
Phase
Observational
Started
2025-10-08
Last updated
2025-11-19

Condition(s) studied

Physiological Responses

Investigational drug(s) / intervention(s)

CinnamaldehydeAllyl isothiocyanate (AITC)Capsaicin

Cinnamaldehyde: A 10% and 30% cinnamaldehyde solution is topically applied on foot skin.

Allyl isothiocyanate (AITC): A 15% and up to 30% AITC solution is topically applied on foot skin.

Capsaicin: A 1.5% and 5% capsaicin solution is topically applied on foot skin.

Study summary

The study aims to characterize the vascular response upon topical application of cinnamaldehyde, allyl isothiocyanate and capsaicin on feet skin in healthy volunteers. The vascular response will be characterized in terms of response over time, dose-response, inter-foot and inter-period reproducibility.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Subject is a white male or female ≥18 and ≤45 years of age 2. Subject is a non-smoker for at least 6 months prior to the start of the study 3. Subject has a body mass index (BMI) between 18-30 kg/m² 4. Subject is judged to be in good general health on the basis of medical history, physical examination and vital signs 5. Subject understands the procedures and agrees to participate in the study by giving written informed consent. Exclusion Criteria: 1. Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study 2. Subject has a history of significant severe (drug) allergies 3. Subject is a female who is pregnant, breast-feeding or intends to become pregnant, or is of child-bearing potential and is not using an adequate contraceptive method 4. Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study 5. Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the feet on a regular basis which cannot be discontinued for the duration of the study 6. Subject has eczema, scleroderma, psoriasis, dermatitis or keloids, tumors, ulcers, burns, skin flaps or grafts on the volar surface of the forearm or the dorsum of the feet, or any other skin abnormality that, in the opinion of the investigator, may interfere with the study assessments 7. Subject has excessive hair growth on the volar surface of the forearms or the dorsum of the feet 8. Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate \<40 or \>100 beats/min, Diastolic Blood Pressure \<50 or \>90 mmHg, Systolic Blood Pressure \<90 or \>140 mmHg 9. Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study 10. Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of illegal drugs, or has a history of substance abuse (including alcohol) 11. Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks 12. Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study

Primary outcome measure(s)

  • Dermal Blood Flow response (PU) — Up until 60 minutes after cinnamaldehyde and AITC application; and up until 90 minutes after capsaicin application.
    The DBF response prior to and at each point in time after topical application of cinnamaldehyde, AITC and capsaicin on the foot, assessed with LSCI, within the area of application, expressed in arbitrary perfusion units (PU).
  • Flare area (mm²) — Up until 60 minutes after cinnamaldehyde and AITC application; and up until 90 minutes after capsaicin application.
    The flare area of the DBF response prior to and at each point in time after topical application of cinnamaldehyde, AITC and capsaicin on the feet, assessed with LSCI.

Trial sites (1)

FacilityCityRegionStatus
Center for Clinical Pharmacology Leuven Belgium Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07237022 on ClinicalTrials.gov ↗ ← All trials in Belgium